SB 1024 revises Missouri’s controlled-substances law to place additional limits and counseling requirements on opioid prescribing. The bill generally prohibits a practitioner, other than a veterinarian, from issuing an initial opioid prescription for more than a seven-day supply when treating acute pain, unless the practitioner determines more medication is medically necessary and documents the reason in the patient’s record. Before issuing an initial opioid prescription, the practitioner must discuss the quantity, the patient’s option to fill a smaller amount, and the risks associated with the opioid. The bill also requires broader risk counseling before an initial Schedule II opioid or other opioid pain reliever prescription, and again before a third prescription in the same course of treatment for acute or chronic pain.
The bill also maintains or clarifies existing supply limits for controlled substances more generally, including a 30-day limit for Schedule II drugs and a 90-day limit for Schedule III-V drugs, with limited exceptions and documentation-based increases. It exempts certain patients and settings from the new opioid counseling and seven-day limits, including cancer patients, people with sickle cell disease, hospice or palliative care patients, residents of licensed long-term care facilities, and patients receiving substance abuse or opioid dependence treatment. Pharmacists are protected from discipline or liability when dispensing or refusing to dispense in good faith under a valid prescription that exceeds the new limits.
SB 1024 would amend section 195.080, RSMo, and directly affect prescribing and dispensing practices for opioids and other controlled substances in Missouri. It would impose new documentation and patient-consultation duties on practitioners, create a default seven-day cap for initial opioid prescriptions for acute pain, and reinforce existing quantity limits for Schedule II through V controlled substances. The bill would also provide liability protection for pharmacists acting in good faith and preserve exceptions for certain medical conditions and care settings, thereby changing how physicians, pharmacists, hospitals, long-term care facilities, hospice providers, and addiction-treatment providers handle opioid prescriptions.
The available context suggests the bill is framed as a public-health and opioid-stewardship measure, with no recorded committee debate or votes indicating opposition or amendment activity. The caption and text reflect a policy approach focused on reducing unnecessary opioid exposure, improving informed consent, and encouraging nonopioid alternatives. Because there are no transcripts or vote records provided, the overall sentiment can only be characterized as neutral-to-supportive based on the bill’s preventive and safety-oriented design.
The main points of potential contention are the seven-day initial prescription limit, the added counseling and documentation requirements, and the extent to which prescribers should retain discretion to exceed the cap. Physicians may view the bill as adding administrative burden or constraining clinical judgment, while supporters would likely argue that the exceptions and medical-necessity override preserve flexibility. Pharmacists are also implicated, but the bill attempts to shield them from liability when acting in good faith, which may reduce concern on that side. The broad exemptions for cancer, sickle cell disease, hospice, palliative care, long-term care, and substance-use treatment suggest an effort to balance opioid control with access for patients with serious or chronic conditions.